Each Friday, we provide an update on the current live tracking portfolio (as of the previous day’s closing prices), a summary of the last week of trading activity, and updates on any significant developments among the companies we have positions in.
Investors are concerned that the products of the company featured this month are on the wrong side of history and condemned to permanent decline. This report will explain how the company is reinventing itself – and will remain a survivor – and propelling the price of its bond higher.
If you’ve missed out on Bitcoin’s and Ethereum’s meteoric rise, this month’s issue of Tech Frontiers is for you. If you’ve ridden these meteors, congratulations – this issue will offer you a thoughtful way to diversify your gains and stay onboard.
A global version of Berkshire Hathaway, this Japanese firm doesn’t merely own a collection of great businesses, it controls entire industries, but never directly.
Japan is controlled by powerful families that are hidden from the public. They control banks, insurance companies, and have privileged access to government capital. Rather than seeking formal control, they sell majority stakes to prominent operators, while always secretly holding the reins of power… Porter discusses their investment powers today.
Unlike most other monetary goods, it is practically impossible to create enough new supply of gold to suppress its price significantly… as it creeps its way up to $4,000 per ounce.
Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for
Last week, Fortress Biotech (Nasdaq: FBIO) issued a press release disclosing that the Food And Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”) for CUTX-101, Fortress’s new drug to treat Menkes disease. A CRL is the FDA’s way of communicating it has decided against approving a new drug application in its current form.